In situ T cells in melanoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1999-09

AUTHORS

Per thor Straten, Jürgen C. Becker, Per Guldberg, Jesper Zeuthen

ABSTRACT

During the past decade new insights have been gained into the role of T lymphocytes in the host's immune response to cancer in general and to melanoma in particular. Several melanoma-associated antigens (MAA) recognized by T cells have been characterized, and a number of HLA class I- and class II-restricted peptides have been identified. These antigens can be divided into three different groups: tumor-associated testis-specific antigens, melanocyte differentiation antigens, and mutated or aberrantly expressed antigens. These proteins give rise to several antigenic peptides. The number of known melanoma-associated peptides that can induce killing by cytotoxic T-lymphocytes (CTL) exceeds 30 and is still increasing. In line with these findings, clinical data indicate that the immune system is essential in the control of tumor growth. A brisk infiltration of lymphocytes is associated with a favorable prognosis, and complete or partial regression of primary melanoma occurs quite frequently. Furthermore, immunomodulatory therapies have accomplished complete or partial tumor regression in a number of patients. However, the immune response is in most cases inadequate to control tumor growth as tumor progression often occurs. Hence, the coexistence of a cellular immune response in melanoma lesions, demonstrated by the presence of clonally expanded T cells, remains a major paradox of tumor immunology. In the present paper we review current knowledge regarding tumor infiltrating lymphocytes (TIL) in melanoma and discuss possible mechanisms of escape from immune surveillance. More... »

PAGES

386-395

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s002620050591

DOI

http://dx.doi.org/10.1007/s002620050591

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1018995967

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/10501852


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antigens, CD", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antigens, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "CD3 Complex", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Division", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunoglobulin Variable Region", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunophenotyping", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphocytes, Tumor-Infiltrating", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Melanoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Antigen, T-Cell, alpha-beta", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "T-Lymphocytes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Escape", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Tumor Cell Biology, Danish Cancer Society, Copenhagen, Denmark, DK", 
          "id": "http://www.grid.ac/institutes/grid.417390.8", 
          "name": [
            "Department of Tumor Cell Biology, Danish Cancer Society, Copenhagen, Denmark, DK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "thor Straten", 
        "givenName": "Per", 
        "id": "sg:person.01065663541.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065663541.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Dermatology, Julius-Maximillians-University, W\u00fcrzburg, Germany, DE", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Dermatology, Julius-Maximillians-University, W\u00fcrzburg, Germany, DE"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Becker", 
        "givenName": "J\u00fcrgen C.", 
        "id": "sg:person.010752465752.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010752465752.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Tumor Cell Biology, Danish Cancer Society, Copenhagen, Denmark, DK", 
          "id": "http://www.grid.ac/institutes/grid.417390.8", 
          "name": [
            "Department of Tumor Cell Biology, Danish Cancer Society, Copenhagen, Denmark, DK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Guldberg", 
        "givenName": "Per", 
        "id": "sg:person.0760021664.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760021664.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Tumor Cell Biology, Danish Cancer Society, Copenhagen, Denmark, DK", 
          "id": "http://www.grid.ac/institutes/grid.417390.8", 
          "name": [
            "Department of Tumor Cell Biology, Danish Cancer Society, Copenhagen, Denmark, DK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zeuthen", 
        "givenName": "Jesper", 
        "id": "sg:person.014230306111.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014230306111.38"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1999-09", 
    "datePublishedReg": "1999-09-01", 
    "description": "Abstract During the past decade new insights have been gained into the role of T lymphocytes in the host's immune response to cancer in general and to melanoma in particular. Several melanoma-associated antigens (MAA) recognized by T cells have been characterized, and a number of HLA class I- and class II-restricted peptides have been identified. These antigens can be divided into three different groups: tumor-associated testis-specific antigens, melanocyte differentiation antigens, and mutated or aberrantly expressed antigens. These proteins give rise to several antigenic peptides. The number of known melanoma-associated peptides that can induce killing by cytotoxic T-lymphocytes (CTL) exceeds 30 and is still increasing. In line with these findings, clinical data indicate that the immune system is essential in the control of tumor growth. A brisk infiltration of lymphocytes is associated with a favorable prognosis, and complete or partial regression of primary melanoma occurs quite frequently. Furthermore, immunomodulatory therapies have accomplished complete or partial tumor regression in a number of patients. However, the immune response is in most cases inadequate to control tumor growth as tumor progression often occurs. Hence, the coexistence of a cellular immune response in melanoma lesions, demonstrated by the presence of clonally expanded T cells, remains a major paradox of tumor immunology. In the present paper we review current knowledge regarding tumor infiltrating lymphocytes (TIL) in melanoma and discuss possible mechanisms of escape from immune surveillance.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s002620050591", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1096240", 
        "issn": [
          "0340-7004", 
          "1432-0851"
        ], 
        "name": "Cancer Immunology, Immunotherapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "7", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "48"
      }
    ], 
    "keywords": [
      "melanoma-associated antigens", 
      "immune response", 
      "tumor-associated testis-specific antigens", 
      "tumor growth", 
      "melanoma-associated peptides", 
      "partial tumor regression", 
      "cellular immune responses", 
      "number of patients", 
      "HLA class I", 
      "host immune response", 
      "testis-specific antigens", 
      "brisk infiltration", 
      "immunomodulatory therapy", 
      "favorable prognosis", 
      "cytotoxic T", 
      "tumor immunology", 
      "tumor regression", 
      "T cells", 
      "clinical data", 
      "immune surveillance", 
      "primary melanoma", 
      "immune system", 
      "melanoma lesions", 
      "class II", 
      "tumor progression", 
      "partial regression", 
      "lymphocytes", 
      "class I", 
      "antigen", 
      "antigenic peptides", 
      "melanoma", 
      "current knowledge", 
      "possible mechanism", 
      "melanocyte differentiation", 
      "cells", 
      "past decade new insight", 
      "peptides", 
      "most cases", 
      "response", 
      "prognosis", 
      "regression", 
      "patients", 
      "therapy", 
      "lesions", 
      "tumors", 
      "cancer", 
      "different groups", 
      "progression", 
      "infiltration", 
      "immunology", 
      "surveillance", 
      "killing", 
      "major paradox", 
      "group", 
      "findings", 
      "new insights", 
      "number", 
      "differentiation", 
      "control", 
      "cases", 
      "role", 
      "protein", 
      "presence", 
      "growth", 
      "mechanism", 
      "escape", 
      "data", 
      "lines", 
      "knowledge", 
      "rise", 
      "Abstract", 
      "insights", 
      "coexistence", 
      "system", 
      "paradox", 
      "present paper", 
      "paper", 
      "decade new insights", 
      "situ T cells"
    ], 
    "name": "In situ T cells in melanoma", 
    "pagination": "386-395", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1018995967"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s002620050591"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "10501852"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s002620050591", 
      "https://app.dimensions.ai/details/publication/pub.1018995967"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:13", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_343.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s002620050591"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s002620050591'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s002620050591'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s002620050591'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s002620050591'


 

This table displays all metadata directly associated to this object as RDF triples.

213 TRIPLES      21 PREDICATES      118 URIs      110 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s002620050591 schema:about N2bf8f2ecc22d4613a351c13872a764d7
2 N55a91713e4374c2d93d70be9ac51d85f
3 N649ec31baf114e4896ab31316fc0a957
4 N7769dc8cf61b402d8b46040e425e448d
5 N9315d007e3f9415c8b3082214e76e1aa
6 N9a8a735d9c0e4a73ac86389de46aee95
7 Nb5493639e3f14c7f92f3463bfd5e3171
8 Nbac84175b68d439ab8cb01209e70adaa
9 Nc0c54b62c63a47e0a4c41bc7ccc380d3
10 Nc3089355761b4818b3506012c5f5000e
11 Nc7ce184ce906420f92c90d4ca02338ad
12 Nfc87ece2e0b5424f85502f3275c8ea71
13 anzsrc-for:11
14 anzsrc-for:1107
15 schema:author Nf12a4658c98d46ffaa8a0f3d9dc6eb29
16 schema:datePublished 1999-09
17 schema:datePublishedReg 1999-09-01
18 schema:description Abstract During the past decade new insights have been gained into the role of T lymphocytes in the host's immune response to cancer in general and to melanoma in particular. Several melanoma-associated antigens (MAA) recognized by T cells have been characterized, and a number of HLA class I- and class II-restricted peptides have been identified. These antigens can be divided into three different groups: tumor-associated testis-specific antigens, melanocyte differentiation antigens, and mutated or aberrantly expressed antigens. These proteins give rise to several antigenic peptides. The number of known melanoma-associated peptides that can induce killing by cytotoxic T-lymphocytes (CTL) exceeds 30 and is still increasing. In line with these findings, clinical data indicate that the immune system is essential in the control of tumor growth. A brisk infiltration of lymphocytes is associated with a favorable prognosis, and complete or partial regression of primary melanoma occurs quite frequently. Furthermore, immunomodulatory therapies have accomplished complete or partial tumor regression in a number of patients. However, the immune response is in most cases inadequate to control tumor growth as tumor progression often occurs. Hence, the coexistence of a cellular immune response in melanoma lesions, demonstrated by the presence of clonally expanded T cells, remains a major paradox of tumor immunology. In the present paper we review current knowledge regarding tumor infiltrating lymphocytes (TIL) in melanoma and discuss possible mechanisms of escape from immune surveillance.
19 schema:genre article
20 schema:inLanguage en
21 schema:isAccessibleForFree false
22 schema:isPartOf N7273a1cb2c294c5ebfd93077d14c8afd
23 Nba104c5be7ca4c538b0f8b3c35648228
24 sg:journal.1096240
25 schema:keywords Abstract
26 HLA class I
27 T cells
28 antigen
29 antigenic peptides
30 brisk infiltration
31 cancer
32 cases
33 cells
34 cellular immune responses
35 class I
36 class II
37 clinical data
38 coexistence
39 control
40 current knowledge
41 cytotoxic T
42 data
43 decade new insights
44 different groups
45 differentiation
46 escape
47 favorable prognosis
48 findings
49 group
50 growth
51 host immune response
52 immune response
53 immune surveillance
54 immune system
55 immunology
56 immunomodulatory therapy
57 infiltration
58 insights
59 killing
60 knowledge
61 lesions
62 lines
63 lymphocytes
64 major paradox
65 mechanism
66 melanocyte differentiation
67 melanoma
68 melanoma lesions
69 melanoma-associated antigens
70 melanoma-associated peptides
71 most cases
72 new insights
73 number
74 number of patients
75 paper
76 paradox
77 partial regression
78 partial tumor regression
79 past decade new insight
80 patients
81 peptides
82 possible mechanism
83 presence
84 present paper
85 primary melanoma
86 prognosis
87 progression
88 protein
89 regression
90 response
91 rise
92 role
93 situ T cells
94 surveillance
95 system
96 testis-specific antigens
97 therapy
98 tumor growth
99 tumor immunology
100 tumor progression
101 tumor regression
102 tumor-associated testis-specific antigens
103 tumors
104 schema:name In situ T cells in melanoma
105 schema:pagination 386-395
106 schema:productId N56f4bb0b7758434886c4ebec1ff3f869
107 N9c52f78beea64479917a1ebaa4befd06
108 Nb2d0721643834792aab81fbc5d6d1db6
109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018995967
110 https://doi.org/10.1007/s002620050591
111 schema:sdDatePublished 2021-12-01T19:13
112 schema:sdLicense https://scigraph.springernature.com/explorer/license/
113 schema:sdPublisher N17bcaba3e6b74a0d89bd631c9e6bf7e5
114 schema:url https://doi.org/10.1007/s002620050591
115 sgo:license sg:explorer/license/
116 sgo:sdDataset articles
117 rdf:type schema:ScholarlyArticle
118 N17bcaba3e6b74a0d89bd631c9e6bf7e5 schema:name Springer Nature - SN SciGraph project
119 rdf:type schema:Organization
120 N2bf8f2ecc22d4613a351c13872a764d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Immunophenotyping
122 rdf:type schema:DefinedTerm
123 N39874c4d035a4aaaa9159008fe0d6001 rdf:first sg:person.0760021664.46
124 rdf:rest N5f65735644024f55878d558ff5773baa
125 N55a91713e4374c2d93d70be9ac51d85f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Cell Division
127 rdf:type schema:DefinedTerm
128 N56f4bb0b7758434886c4ebec1ff3f869 schema:name pubmed_id
129 schema:value 10501852
130 rdf:type schema:PropertyValue
131 N5b6ccac9044d4ab39ea471751485befb rdf:first sg:person.010752465752.66
132 rdf:rest N39874c4d035a4aaaa9159008fe0d6001
133 N5f65735644024f55878d558ff5773baa rdf:first sg:person.014230306111.38
134 rdf:rest rdf:nil
135 N649ec31baf114e4896ab31316fc0a957 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Immunoglobulin Variable Region
137 rdf:type schema:DefinedTerm
138 N7273a1cb2c294c5ebfd93077d14c8afd schema:issueNumber 7
139 rdf:type schema:PublicationIssue
140 N7769dc8cf61b402d8b46040e425e448d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name T-Lymphocytes
142 rdf:type schema:DefinedTerm
143 N9315d007e3f9415c8b3082214e76e1aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Receptors, Antigen, T-Cell, alpha-beta
145 rdf:type schema:DefinedTerm
146 N9a8a735d9c0e4a73ac86389de46aee95 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Antigens, Neoplasm
148 rdf:type schema:DefinedTerm
149 N9c52f78beea64479917a1ebaa4befd06 schema:name doi
150 schema:value 10.1007/s002620050591
151 rdf:type schema:PropertyValue
152 Nb2d0721643834792aab81fbc5d6d1db6 schema:name dimensions_id
153 schema:value pub.1018995967
154 rdf:type schema:PropertyValue
155 Nb5493639e3f14c7f92f3463bfd5e3171 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Lymphocytes, Tumor-Infiltrating
157 rdf:type schema:DefinedTerm
158 Nba104c5be7ca4c538b0f8b3c35648228 schema:volumeNumber 48
159 rdf:type schema:PublicationVolume
160 Nbac84175b68d439ab8cb01209e70adaa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Melanoma
162 rdf:type schema:DefinedTerm
163 Nc0c54b62c63a47e0a4c41bc7ccc380d3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Antigens, CD
165 rdf:type schema:DefinedTerm
166 Nc3089355761b4818b3506012c5f5000e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Humans
168 rdf:type schema:DefinedTerm
169 Nc7ce184ce906420f92c90d4ca02338ad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name CD3 Complex
171 rdf:type schema:DefinedTerm
172 Nf12a4658c98d46ffaa8a0f3d9dc6eb29 rdf:first sg:person.01065663541.26
173 rdf:rest N5b6ccac9044d4ab39ea471751485befb
174 Nfc87ece2e0b5424f85502f3275c8ea71 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Tumor Escape
176 rdf:type schema:DefinedTerm
177 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
178 schema:name Medical and Health Sciences
179 rdf:type schema:DefinedTerm
180 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
181 schema:name Immunology
182 rdf:type schema:DefinedTerm
183 sg:journal.1096240 schema:issn 0340-7004
184 1432-0851
185 schema:name Cancer Immunology, Immunotherapy
186 schema:publisher Springer Nature
187 rdf:type schema:Periodical
188 sg:person.01065663541.26 schema:affiliation grid-institutes:grid.417390.8
189 schema:familyName thor Straten
190 schema:givenName Per
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065663541.26
192 rdf:type schema:Person
193 sg:person.010752465752.66 schema:affiliation grid-institutes:None
194 schema:familyName Becker
195 schema:givenName Jürgen C.
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010752465752.66
197 rdf:type schema:Person
198 sg:person.014230306111.38 schema:affiliation grid-institutes:grid.417390.8
199 schema:familyName Zeuthen
200 schema:givenName Jesper
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014230306111.38
202 rdf:type schema:Person
203 sg:person.0760021664.46 schema:affiliation grid-institutes:grid.417390.8
204 schema:familyName Guldberg
205 schema:givenName Per
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760021664.46
207 rdf:type schema:Person
208 grid-institutes:None schema:alternateName Department of Dermatology, Julius-Maximillians-University, Würzburg, Germany, DE
209 schema:name Department of Dermatology, Julius-Maximillians-University, Würzburg, Germany, DE
210 rdf:type schema:Organization
211 grid-institutes:grid.417390.8 schema:alternateName Department of Tumor Cell Biology, Danish Cancer Society, Copenhagen, Denmark, DK
212 schema:name Department of Tumor Cell Biology, Danish Cancer Society, Copenhagen, Denmark, DK
213 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...